Evidence map›Paper›PMID 40828324›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

The impact of para-hydroxycinnamic acid on myofibroblast trans-differentiation in MRC-5 and A549 cell lines: in silico and in vitro evaluation.

Nada Sahib Shaker, Zeena Ayad Hussein, Samer Tariq Jasim, Ahmed Rahmah Abu-Raghif

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nada Sahib ShakerDepartment of Pharmacology & Toxicology, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq.ORCID http://orcid.org/0000-0003-1019-8105
Zeena Ayad HusseinDepartment of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq. zeena.kanada@nahrainuniv.edu.iq.ORCID http://orcid.org/0000-0001-7011-5186
Samer Tariq JasimDepartment of Pharmaceutical Chemistry, College of Pharmacy, Imam Ja'afar AL-Sadiq University, Baghdad, Iraq.ORCID http://orcid.org/0009-0000-6004-2120
Ahmed Rahmah Abu-RaghifDepartment of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq.ORCID http://orcid.org/0000-0003-4514-3892

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrosis-related disorders like pulmonary fibrosis are chronically progressive disorders characterized by tissue scarring with a gradual decline in function. Transforming growth factor-beta1 (TGF-β1), myofibroblast trans-differentiation, and epithelial to mesenchymal transition (EMT) play a central role in fibrosis progression. Para-hydroxycinnamic acid is a naturally occurring phenolic acid metabolite having different biological activities. This study aimed to investigate the potential of para-hydroxycinnamic acid (p-HCA) in inhibiting the epithelial-mesenchymal transition in vitro and to understand the mechanism of action using in silico analysis. Molecular docking analysis was executed using Schrodinger Glide software with four selected protein targets (caspase-1, lysophosphatidic acid receptor 1, peroxisome proliferator-activated receptor-gamma, and NLRP3). In vitro studies used human normal fetal lung fibroblasts (MRC-5) and cancerous alveolar epithelial cells (A549). The MTT assay for cytotoxicity analysis was applied to p-HCA (the test agent) and pirfenidone (PFD/the standard comparator) at serial concentrations ranging from 100 to 6.25 µg/ml. Both cell lines were treated with 100 µg/ml of p-HCA and PFD following a previous induction with 10 ng/ml TGF-β1 and then incubated for 48 h. Gene expression analysis was performed using qRT-PCR for EMT genes, including α-smooth muscle actin, fibronectin, vimentin, and Smad2/3. Results revealed that p-HCA had favorable binding affinities for lysophosphatidic acid receptor 1 and PPAR-γ, with a good receptor pose, which is complemented by the in vitro results, in which p-HCA exhibited low cytotoxicity potential towards MRC-5 with IC50 191.8 µg/ml and mild cytotoxicity for A549 with IC50 34.34 µg/ml. Results of the gene expression evaluation showed a statistically significant reduction (P < 0.001) in the gene expression of all myofibroblast trans-differentiation markers by over twofold compared with the TGF-β1-induced cells and no significant difference (P > 0.05) compared with the PFD. p-HCA can halt myofibroblast formation and EMT in both MRC-5 and A549 through indirect influence on the TGF-β1/Smad2/3 pathway by interaction with LPAR1 and PPAR-γ, making it a promising agent to investigate further in pharmaceutical and clinical settings.

Indexed as

Cell TransdifferentiationCoumaric AcidsMyofibroblastsA549 CellsCell LineCell SurvivalEpithelial-Mesenchymal TransitionHumansMolecular Docking SimulationPPAR gammaReceptors, Lysophosphatidic AcidTransforming Growth Factor beta1Coumaric AcidsLPAR1 protein, humanPPAR gammaPPARG protein, humanReceptors, Lysophosphatidic AcidTransforming Growth Factor beta1Gene expressionIn vitroMolecular dockingMyofibroblastsPara-hydroxycinnamic acidPirfenidone

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.